Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730)

Journal of Clinical Oncology

Volumn 23, Issue 1, 2005, Pages 190-196

  Lilenbaum, Rogerio C ^a   Herndon II, James E ^b   List, Marcy A ^b   Desch, Chris ^b   Watson, Dorothy M ^b   Miller, Antonius A ^b   Graziano, Stephen L ^b   Perry, Michael C ^b   Saville, Wayne ^b   Chahinian, Philippe ^b   Weeks, Jane C ^b   Holland, Jimmie C ^b   Green, Mark R ^b  

^a Mount Sinai Comprehensive Cancer Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; INFECTION; LEUKEMIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING; COMPARATIVE STUDY; LUNG TUMOR; MIDDLE AGED; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE;

EID: 16644396077     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.172     Document Type: Article

References (15)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics 2003. CA Cancer J Clin 53:5-26, 2003
2. Non-Small Cell Lung Cancer Co-Operative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
3. Cullen M, Billingham J, Woodraffe C, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17:3188-3194, 1999
4. Kelly K, Crowley J, Bunn PA, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002
6. Rodriguez J, Pawel J, Pluzanska A, et al: A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) vs. vinorelbine + cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 20:20a, 2001 (abstr 1252)
7. Lilenbaum R, Langenberg P, Dickersin K: Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma: A meta-analysis of response, toxicity, and survival. Cancer 82:116-126, 1998
8. Schiller JH, Bernardo P, Harrington D, et al: Comparison of outcome and patient characteristics in advanced non-small cell lung cancer: Analysis of Eastern Cooperative Oncology Group trials from 1980-2000. Proc Am Soc Clin Oncol 21:304a, 2002 (abstr 1215)
9. Shepherd F, Dancey J, Ramlau R, et al: A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
10. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000
11. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002
12. Kelly K, Giarritta S, Hayes S, et al: Should older patients receive combination chemotherapy for advanced non-small cell lung cancer? An analysis of Southwest Oncology trials 9509 and 9308. Proc Am Soc Clin Oncol 20:329a, 2001 (abstr 1313)
13. Gridelli C, Perronet F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003
14. Bunn P, Lilenbaum R: Chemotherapy for elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 95:341-343, 2003
15. Sweeney C, Zhu J, Sandler A, et al: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in metastatic non-small cell lung carcinoma. Cancer 92:2635-2647, 2001